Title : Multimodal assessment of rheumatoid arthritis: Coupling musculoskeletal imaging, immune biomarkers and disease progression using BVidAL clinical software suite
Abstract:
Rheumatoid Arthritis (RA) is a chronic, systemic, immune-mediated inflammatory disease characterized by synovial inflammation, progressive cartilage degradation, bone erosion, and variable extra-articular manifestations. Conventional clinical assessment relies on laboratory biomarkers, clinical examination, and musculoskeletal imaging, which provide complementary but sometimes discordant information. Integrating these heterogeneous observations within a coherent computational framework remains an important challenge for longitudinal disease assessment and therapeutic research. This work presents a research-oriented, multimodal computational approach based on the proposed Bansal-biology (b-bio) methodolgy, comprising nine proposed novel frameworks built upon five foundational architectures, and its implementation within BVidAL clinical software suite. The approach aims to represent relationships among autoimmune activity, joint structural abnormalities, inflammatory burden, therapeutic interventions, and musculoskeletal disease progression. The proposed methodology combines radiographic joint-space assessment, Magnetic Resonance Imaging (MRI) findings, and immune-inflammatory laboratory evidence, including Rheumatoid Factor (RF), Anti-Cyclic Citrullinated Peptide antibodies (anti-CCP), Erythrocyte Sedimentation Rate (ESR), and C-Reactive Protein (CRP). Musculoskeletal imaging components support the identification and quantitative characterization of candidate abnormalities involving synovitis, bone marrow edema, cartilage, joint effusion, and structural changes. These observations are represented through stratified biological and disease-state layers incorporating inflammatory, autoimmune, structural, and biomechanical components. For exploratory drug-testing and drug-development applications, the computational architecture includes therapeutic evaluation pathways for conventional disease-modifying antirheumatic drugs (dmards), including methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide; biologic agents including adalimumab, etanercept, and tocilizumab; and Janus Kinase (JAK) inhibitors including tofacitinib, baricitinib, and upadacitinib, on a digital twin. The proposed in silico methodology supports class-based therapeutic-response simulation, subject to appropriate pk/pd evidence and model verification, with exploratory assessment of inflammatory burden, pain, functional impairment, and longitudinal disease-state perturbations. Further disease-specific integration, reproducible patient-data studies, quantitative drug-response verification, comparison with established clinical activity measures, and independent validation are required to establish its clinical applicability.
Keywords: Rheumatoid Arthritis, Bansal-Biology, Bansal Framework, Clinical Immunology, Musculoskeletal Imaging, Immune Biomarkers, Stratified Disease-State Modeling, Digital Twin, Dmards, In Silico Drug Testing, BVidAL Clinical Software Suite.
